Intravenous Tapentadol in Post-Bunionectomy Pain

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (103 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 25.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painacutemultiplepatients mustimpaired
  Phrases that lowered it: efficacyand safetyevaluate theto evaluatesafety of
• Phase: 2 (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 7.7% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 91.7% (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 31 (lowers risk) · Sponsor's track record
• Maximum age: 65 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 9 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 292 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy. NCT00613938 · started 2008 · scored riskier than 31% of active trials completed
• A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy NCT01516008 · started 2012 · scored riskier than 59% of active trials completed
• A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo NCT01813890 · started 2013 · scored riskier than 17% of active trials completed
• A Study of TRV130 for the Treatment of Pain After Bunionectomy NCT02100748 · started 2014 · scored riskier than 21% of active trials completed
• Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy NCT03290378 · started 2017 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.